Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting

(2012) K. Goto et al.   ANNALS OF ONCOLOGY

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny

(2012) Kenichi Suda et al.   CANCER AND METASTASIS REVIEWS

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy

(2012) Fumihiro Yamaguchi et al.   LUNG CANCER

Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment

(2012) HONG-YANG LU et al.   Oncology Letters

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung

(2011) Xiao-Li Jia et al.   LUNG CANCER

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung

(2010) Naheed Alam et al.   Clinical Lung Cancer

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency of and variables associated with the EGFR mutation and its subtypes

(2009) Tomoaki Tanaka et al.   INTERNATIONAL JOURNAL OF CANCER

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

(2008) D. B. Costa et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer

(2008) A. Tatematsu et al.   CLINICAL CANCER RESEARCH

Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations

(2008) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY